EU approves AstraZeneca's Tezspire to treat nasal conditions

(Sharecast News) - AstraZeneca and Amgen on Monday said their Tezspire drug has been recommended for approval in the European Union for the treatment of adult patients with chronic rhinosinusitis with nasal polyps. The European Medicines Agency based its positive opinion on results from a phase 3 trial, which demonstrated a "statistically significant and clinically meaningful reduction" in nasal polyp severity" and removed the need for surgery in 98% of cases.

Chronic rhinosinusitis with nasal polyps is a chronic inflammatory condition characterised by persistent inflammation and benign polyp growths within the nasal cavity that can obstruct airflow and impair sense of smell, taste and sleep.

The condition affects up to roughly 320 million people worldwide. Nearly half of the patients diagnosed with it in Europe remain uncontrolled, and for many patients, current therapies such as systemic corticosteroids and repeated sinus surgeries do not offer lasting relief, the two companies added in a joint statement.

Reporting by Frank Prenesti for Sharecast.com